Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Nuwellis Inc — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77 (market cap $3.06B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is far larger — about 1390.9× Nuwellis Inc's market cap, and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF for 16 Days and Nuwellis Inc for 26 Days on average.
| FLRN | NUWE | |
|---|---|---|
Market Cap | $3.06B | $2.20M |
Volume | 6,296,473 | 121,544 |
Sector | Fixed Income | Health |
52-Week High | $30.86 | $146.65 |
52-Week Low | $30.65 | $0.68 |
Typical Hold Time | 16 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLRN (SPDR Bloomberg Investment Grade Floating Rate ETF) trades at $30.77 with minimal daily movement (+0.07%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The ETF maintains consistent quarterly dividends of $0.11, with recent institutional buying interest from Concurrent Investment Advisors. Current market focus centers on floating rate bonds' performance amid rising interest rate expectations.
FLRN offers exposure to investment-grade floating rate bonds with near-zero duration, positioning it as a potential hedge against rate hikes. Key risks include concentrated financial sector exposure and sensitivity to credit spread changes. The ETF's structure provides income stability but faces headwinds from potential economic slowdowns affecting corporate bond markets.
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
